{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:49:20Z","timestamp":1791319760569,"version":"4.3.1"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2021-0152_abs_001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with favorable short- and long-term oncological outcomes in highly selected patients with peritoneal metastasis (PM). The aim of our review was to review published, recruiting or ongoing randomized controlled trials (RCTs) evaluating CRS and HIPEC vs. other strategies (systemic chemotherapy or CRS alone) and to update the studies recently described in 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0152_abs_002\">\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>Systematic review according to PRISMA guidelines. Searches for published and ongoing trials were based, respectively, on PubMed and international clinical databases since 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0152_abs_003\">\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>46 trials randomized 9,063 patients: 13 in colorectal cancer (3 in therapeutic strategy and 10 in prophylactic strategy), 16 in gastric cancer (4 in therapeutic strategy and 12 in prophylactic strategy) and 17 in ovarian cancer (12 in front-line therapy and 5 in recurrence settings).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0152_abs_004\">\n                    <jats:title>Outlook<\/jats:title>\n                    <jats:p>In contrast to many recruiting studies, few published studies analyzed the potential advantage of CRS and HIPEC in therapeutic and prophylactic treatment of PM. The potential effect of this combined treatment has been proven in ovarian cancer in interval surgery, but remains still debated in other situations. Promising trials are currently recruiting to provide further evidence of the effectiveness of CRS and HIPEC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2021-0152","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:57:30Z","timestamp":1647305850000},"page":"51-61","source":"Crossref","is-referenced-by-count":19,"title":["Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review"],"prefix":"10.1515","volume":"7","author":[{"given":"Barbara","family":"Noiret","sequence":"first","affiliation":[{"name":"Department of Digestive and Oncological Surgery, Claude Huriez University Hospital , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Piessen","sequence":"additional","affiliation":[{"name":"Department of Digestive and Oncological Surgery, Claude Huriez University Hospital , Lille , France"},{"name":"UMR-S1277 - CANTHER laboratory \u201cCancer Heterogeneity, Plasticity and Resistance to Therapies\u201d , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Eveno","sequence":"additional","affiliation":[{"name":"Department of Digestive and Oncological Surgery, Claude Huriez University Hospital , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"2025120909241448387_j_pp-2021-0152_ref_001","doi-asserted-by":"crossref","unstructured":"Bonnot, P-E, Piessen, G, Kepenekian, V, Decullier, E, Pocard, M, Meunier, B, et al.. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 2019;37:2028\u201340. https:\/\/doi.org\/10.1200\/jco.18.01688.","DOI":"10.1200\/JCO.18.01688"},{"key":"2025120909241448387_j_pp-2021-0152_ref_002","doi-asserted-by":"crossref","unstructured":"Hotouras, A, Desai, D, Bhan, C, Murphy, J, Lampe, B, Sugarbaker, PH. Heated IntraPEritoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer 2016;26:661\u201370. https:\/\/doi.org\/10.1097\/igc.0000000000000664.","DOI":"10.1097\/IGC.0000000000000664"},{"key":"2025120909241448387_j_pp-2021-0152_ref_003","doi-asserted-by":"crossref","unstructured":"Ansari, N, Chandrakumaran, K, Dayal, S, Mohamed, F, Cecil, TD, Moran, BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol 2016;42:1035\u201341. https:\/\/doi.org\/10.1016\/j.ejso.2016.03.017.","DOI":"10.1016\/j.ejso.2016.03.017"},{"key":"2025120909241448387_j_pp-2021-0152_ref_004","doi-asserted-by":"crossref","unstructured":"Yan, TD, Deraco, M, Baratti, D, Kusamura, S, Elias, D, Glehen, O, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Orthod 2009;27:6237\u201342. https:\/\/doi.org\/10.1200\/jco.2009.23.9640.","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"2025120909241448387_j_pp-2021-0152_ref_005","doi-asserted-by":"crossref","unstructured":"Verwaal, VJ, van Ruth, S, de Bree, E, van Sloothen, GW, van Tinteren, H, Boot, H, et al.. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737\u201343. https:\/\/doi.org\/10.1200\/jco.2003.04.187.","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025120909241448387_j_pp-2021-0152_ref_006","doi-asserted-by":"crossref","unstructured":"Elias, D, Gilly, F, Boutitie, F, Quenet, F, Bereder, J-M, Mansvelt, B, et al.. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63\u20138. https:\/\/doi.org\/10.1200\/jco.2009.23.9285.","DOI":"10.1200\/JCO.2009.23.9285"},{"key":"2025120909241448387_j_pp-2021-0152_ref_007","doi-asserted-by":"crossref","unstructured":"Noiret, B, Clement, G, Lenne, X, Bruandet, A, Glehen, O, Voron, T, et al.. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year national French practice. Ann Surg 2020;272:847\u201354.","DOI":"10.1097\/SLA.0000000000004326"},{"key":"2025120909241448387_j_pp-2021-0152_ref_008","doi-asserted-by":"crossref","unstructured":"Eveno, C, Pocard, M. Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review. Pleura Peritoneum 2016;1:169\u201382. https:\/\/doi.org\/10.1515\/pp-2016-0027.","DOI":"10.1515\/pp-2016-0027"},{"key":"2025120909241448387_j_pp-2021-0152_ref_009","doi-asserted-by":"crossref","unstructured":"Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2025120909241448387_j_pp-2021-0152_ref_010","doi-asserted-by":"crossref","unstructured":"Qu\u00e9net, F, Elias, D, Roca, L, Go\u00e9r\u00e9, D, Ghouti, L, Pocard, M, et al.. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:256\u201366.","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"2025120909241448387_j_pp-2021-0152_ref_011","doi-asserted-by":"crossref","unstructured":"Go\u00e9r\u00e9, D, Glehen, O, Quenet, F, Guilloit, J-M, Bereder, J-M, Lorimier, G, et al.. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol 2020;21:1147\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(20)30322-3.","DOI":"10.1016\/S1470-2045(20)30322-3"},{"key":"2025120909241448387_j_pp-2021-0152_ref_012","doi-asserted-by":"crossref","unstructured":"Klaver, CEL, Wisselink, DD, Punt, CJA, Snaebjornsson, P, Crezee, J, Aalbers, AGJ, et al.. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 2019;4:761\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(19)30239-0.","DOI":"10.1016\/S2468-1253(19)30239-0"},{"key":"2025120909241448387_j_pp-2021-0152_ref_013","doi-asserted-by":"crossref","unstructured":"Rau, B, Lang, H, K\u00f6nigsrainer, A, Gockel, I, Rau, H-G, Seeliger, H, et al.. 1376O the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): a randomized multicentre phase III trial (GASTRIPEC-I-trial). Ann Oncol 2021;32:S1040. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1485.","DOI":"10.1016\/j.annonc.2021.08.1485"},{"key":"2025120909241448387_j_pp-2021-0152_ref_014","unstructured":"Cui, S-Z. A phase III study of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with systemic chemotherapy and cytoreductive surgery (CRS) in the treatment of peritoneal carcinomatosis from gastric cancer [Internet]. clinicaltrials.gov. Report No.: NCT03179579; 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03179579 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_015","unstructured":"Wang, W. A randomized controlled clinical trial of hyperthermic intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastatis [Internet]. clinicaltrials.gov. Report No.: NCT03604614; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03604614 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_016","doi-asserted-by":"crossref","unstructured":"Koemans, WJ, van der Kaaij, RT, Boot, H, Buffart, T, Veenhof, AaFA, Hartemink, KJ, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer 2019;19:420. https:\/\/doi.org\/10.1186\/s12885-019-5640-2.","DOI":"10.1186\/s12885-019-5640-2"},{"key":"2025120909241448387_j_pp-2021-0152_ref_017","unstructured":"Mario Negri Institute for Pharmacological Research. Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in gastric carcinoma at high risk of developing peritoneal carcinomatosis. Short and long-term outcomes evaluation. A collaborative randomized controlled trial of: ACOI, FONDAZIONE AIOM, SIC, SICE, SICO. clinicaltrials.gov. Report No.: NCT03917173; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03917173 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_018","unstructured":"Nordwest, K. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II\/III adenocarcinoma - the phase III \u201cPREVENT\u201d trial of the AIO\/CAOGI\/ACO [Internet]. clinicaltrials.gov. Report No.: NCT04447352; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04447352 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_019","unstructured":"D RP MD, Ph. A randomized, multicenter clinical trial comparing the combination of perioperative FLOT4 chemotherapy and preoperative laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) plus gastrectomy to perioperative FLOT4 chemotherapy and gastrectomy alone in patients with advanced gastric cancer at high risk of peritoneal recurrence [Internet]. clinicaltrials.gov. Report No.: NCT04597294; 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04597294 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_020","doi-asserted-by":"crossref","unstructured":"Glehen, O, Passot, G, Villeneuve, L, Vaudoyer, D, Bin-Dorel, S, Boschetti, G, et al.. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer 2014;14:183. https:\/\/doi.org\/10.1186\/1471-2407-14-183.","DOI":"10.1186\/1471-2407-14-183"},{"key":"2025120909241448387_j_pp-2021-0152_ref_021","doi-asserted-by":"crossref","unstructured":"Fan, B, Bu, Z, Zhang, J, Zong, X, Ji, X, Fu, T, et al.. Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery. BMC Cancer 2021;21:216. https:\/\/doi.org\/10.1186\/s12885-021-07925-2.","DOI":"10.1186\/s12885-021-07925-2"},{"key":"2025120909241448387_j_pp-2021-0152_ref_022","unstructured":"CAMPOS, PV. Hyperthermic intraperitoneal chemotherapy with paclitaxel for the treatment of patients with recurrent or primary advanced ovarian cancer : a randomised phase 3 study [Internet]. clinicaltrials.gov. Report No.: NCT02681432; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02681432 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_023","unstructured":"MD LA. Stage IIIC unresectable epithelial ovarian\/tubal cancer with partial or complete response after 1st line neoadjuvant chemotherapy (3 cycles CBDCA+Paclitaxel): a phase 3 prospective randomized study comparing cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CDDP+Paclitaxel) + 3 cycles CBDCA+Paclitaxel vs cytoreductive surgery alone + 3 cycles CBDCA+Paclitaxel. [Internet]. clinicaltrials.gov. Report No.: NCT01628380; 2014. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01628380 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_024","doi-asserted-by":"crossref","unstructured":"van Driel, WJ, Koole, SN, Sikorska, K, Schagen van Leeuwen, JH, Schreuder, HWR, Hermans, RHM, et al.. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340. https:\/\/doi.org\/10.1056\/nejmoa1708618.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909241448387_j_pp-2021-0152_ref_025","doi-asserted-by":"crossref","unstructured":"Rustin, GJS, Vergote, I, Eisenhauer, E, Pujade-Lauraine, E, Quinn, M, Thigpen, T, et al.. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011;21:419\u201323. https:\/\/doi.org\/10.1097\/igc.0b013e3182070f17.","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"2025120909241448387_j_pp-2021-0152_ref_026","doi-asserted-by":"crossref","unstructured":"Antonio, CCP, Alida, GG, Elena, GG, Roc\u00edo, GS, Jer\u00f3nimo, MG, Luis, ARJ, et al.. Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial. Ann Surg Oncol 2021. https:\/\/doi.org\/10.1245\/s10434-021-11087-7.","DOI":"10.1245\/s10434-021-11087-7"},{"key":"2025120909241448387_j_pp-2021-0152_ref_027","doi-asserted-by":"crossref","unstructured":"Koole, S, van Stein, R, Sikorska, K, Barton, D, Perrin, L, Brennan, D, et al.. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer 2020;30:888\u201392. https:\/\/doi.org\/10.1136\/ijgc-2020-001231.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6100"},{"key":"2025120909241448387_j_pp-2021-0152_ref_028","unstructured":"Centre Oscar Lambret. Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different settings: primary debulking surgery (PDS) and interval debulking surgery (IDS) [Internet]. clinicaltrials.gov. Report No.: NCT03842982; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03842982 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_029","unstructured":"Cui, S-Z. A phase III multicenter prospective randomized controlled clinical trial of HIPEC as NACT and postoperative chemotherapy after interval debulking surgery in the treatment of advanced-stage epithelial ovarian cancer [Internet]. clinicaltrials.gov. Report No.: NCT03180177; 2018. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03180177 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_030","unstructured":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University. A phase III multicenter prospective randomized controlled clinical trial of hyperthermic intraperitoneal chemotherapy in the treatment of advanced-stage epithelial ovarian cancer after cytoreductive surgery [Internet]. clinicaltrials.gov. Report No.: NCT03373058; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03373058 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_031","unstructured":"Second Affiliated Hospital, School of Medicine, University Zhejiang. Multicenter prospective randomized controlled clinical trial of hyperthermic intraperitoneal chemotherapy in the treatment of stage IIc-IV epithelial ovarian cancer after primary cytoreductive surgery [Internet]. clinicaltrials.gov. Report No.: NCT04280185; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280185 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_032","unstructured":"Hospices Civils de Lyon. Assessment of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in first or secondary platinum-resistant recurrent ovarian epithelial cancer [Internet]. clinicaltrials.gov. Report No.: NCT03220932; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03220932 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_033","unstructured":"Padilla-Valverde, D. Intrabdominal hyperthermic chemotherapy using gemcitabine to treat pancreatic carcinomatosis [Internet]. clinicaltrials.gov. Report No.: NCT03251365; 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03251365 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_034","doi-asserted-by":"crossref","unstructured":"Sadeghi, B, Arvieux, C, Glehen, O, Beaujard, AC, Rivoire, M, Baulieux, J, et al.. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358\u201363. https:\/\/doi.org\/10.1002\/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o.","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909241448387_j_pp-2021-0152_ref_035","unstructured":"Mario Negri Institute for Pharmacological Research. Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk peritoneal carcinomatosis. Short and long-term outcomes. A collaborative randomized controlled trial of: ACOI, FONDAZIONE AIOM, SIC, SICE, SICO. CHECK STUDY [Internet]. clinicaltrials.gov. Report No.: NCT03914820; 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914820 [Accessed 1 Apr 2021]."},{"key":"2025120909241448387_j_pp-2021-0152_ref_036","doi-asserted-by":"crossref","unstructured":"Reutovich, MY, Krasko, OV, Sukonko, OG. Hyperthermic intraperitoneal chemotherapy in serosa-invasive gastric cancer patients. Eur J Surg Oncol 2019;45:2405\u201311. https:\/\/doi.org\/10.1016\/j.ejso.2019.07.030.","DOI":"10.1016\/j.ejso.2019.07.030"},{"key":"2025120909241448387_j_pp-2021-0152_ref_037","doi-asserted-by":"crossref","unstructured":"Beeharry, MK, Zhu, Z-L, Liu, W-T, Yao, X-X, Yan, M, Zhu, Z-G. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer 2019;19:932. https:\/\/doi.org\/10.1186\/s12885-019-6125-z.","DOI":"10.1186\/s12885-019-6125-z"},{"key":"2025120909241448387_j_pp-2021-0152_ref_038","unstructured":"UNICANCER. A phase III randomized study evaluating hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of relapse ovarian cancer [Internet]. clinicaltrials.gov. Report No.: NCT01376752; 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01376752 [Accessed 1 Apr 2021]."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0152\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:01:06Z","timestamp":1765278066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0152\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1515\/pp-2021-0152"],"URL":"https:\/\/doi.org\/10.1515\/pp-2021-0152","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}